PRMT3 has been shown to regulate metabolic reprogramming in pancreatic cancers by methylating glycolytic pathway components such as GAPDH and ABCG2 to reprogram cellular metabolism to promote tumor progression [52, 53]. Here, GAPDH is linked to familial pancreatic carcinoma.